Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

BCRX - BioCryst Pharmaceuticals, Inc.... | Finranks

Home

/

BCRX

B

BioCryst Pharmaceuticals, Inc. (BCRX)

NMS – Real vaqt narxi. Valyuta: USD

8.80

+0.22 (2.56%)

Yopilishda: May 12, 2026, 4:00 PM EDT

8.87

+0.07 (0.80%)

Bozordan keyin: May 12, 2026, 7:40 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported upbeat earnings for the first quarter on Wednesday.

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.06. This compares to break-even earnings per share a year ago.

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 61,750 shares of BioCryst common stock. The RSUs were granted as of May 1, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —

Videolar

No Data

There is no data to display

Press-relizlar

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05.05.2026

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 61,750 shares of BioCryst common stock. The RSUs were granted as of May 1, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —